An ally against childhood pneumonia

June 18, 2013 by Pam Auchmutey

(Medical Xpress)—Since 2000, children born in the United States benefit from the research of Keith Klugman, who helped develop the pneumonia vaccine that is now part of their immunization regimen. As a result, invasive pneumococcal disease among young American children has decreased by nearly 80%.

Children are less fortunate in the developing world, where pneumonia claims 800,000 lives annually—more than any other childhood disease. Klugman has made it his life's work to reverse that trend.

When the South African native joined the Rollins School of Public Health in 2001, he was regarded as the world's leading expert on in pneumonia. Four years later, Klugman was named the William H. Foege Chair of Global Health, funded by the Hubert Foundation in honor of Foege's contributions to the field.

In 2003, the New England Journal of Medicine published the results of Klugman's landmark study that proved overwhelmingly that the had the potential to save the lives of thousands of HIV-positive and HIV-negative children. Since then, Klugman has pushed to make the vaccine available to children in Africa and Southeast Asia.

"One challenge in particular is developing the evidence to show that the vaccine, when implemented in routine immunizations, reduces children's deaths," says Klugman. "That is largely the focus of our current research at Rollins."

Klugman's team has begun to evaluate in rural South Africa by looking at the ecology of the pre- and post-vaccine. Ultimately, they expect their results to show that the vaccine protects children up to age 5 and interrupts to unvaccinated children and adults.

Bacteria resistance to vaccines remains an ever-present threat, leading Klugman and several collaborators to embark on the largest project ever to sequence the 20,000 pneumococcal genomes. Researchers will collect strains of the bacteria before and after the vaccine is rolled out in four countries in Africa and analyze existing strains in the United States, Asia, and South America. Through genetic sequencing of these strains, they hope to identify the genomic changes associated with bacterial escape from the .

Pneumonia is the leading cause of death for children globally. For several years, Keith Klugman, MD, has focused on ways to reduce deaths from pneumonia and determined the most effective way is through vaccination.

Klugman is leading the five-year study, funded by the Bill & Melinda Gates Foundation, in collaboration with the CDC, the University of Cambridge in England, the National Institute for Communicable Diseases at Wits University in South Africa, the Wellcome Trust Sanger Institute unit in Malawi, the Medical Research Council in Gambia, and the Kenya Medical Research Institute.

Earlier this year, the Gates Foundation tapped Klugman to serve six months as its senior adviser on pneumonia prevention. Students also benefit from his expertise. A conversation with Klugman led MD/PhD student Michael Mina to study how influenza vaccines may impact diseases caused by bacteria.

Mina remembers that first meeting. "Keith told me, 'I'm fairly confident that the influenza virus is responsible for most pneumococcal disease during flu season.' His comment stuck with me," says Mina. "He has this wonderful ability to think broadly about the different aspects of human biology and disease."

Explore further: Genome sequencing provides unprecedented insight into causes of pneumococcal disease

Related Stories

Genome sequencing provides unprecedented insight into causes of pneumococcal disease

May 5, 2013
A new study led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK has, for the first time, used genome sequencing technology to track the changes in a bacterial population ...

Pneumococcal rates plunge after widespread vaccination of infants

May 27, 2013
The number of young children contracting the most common strains of potentially fatal pneumococcal disease has plummeted 97% since the universal vaccination against this bacterial disease began in 2005, with unvaccinated ...

Newly identified antibodies may improve pneumonia vaccine design

September 22, 2011
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria. The findings, which could improve vaccines against pneumonia, appear ...

2009 H1N1 pandemic flu more damaging to lungs, opens opportunities for bacterial infection

September 19, 2011
Many of the people who died from the new strain of H1N1 influenza that broke out in 2009 were suffering from another infection as well: pneumonia. A new study to be published Tuesday, September 20 in the online journal mBio ...

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.